Founders Fund III Management’s Ensysce Biosciences ENSC Stock Holding History

Founders Fund III Management’s Portfolio ENSC Stock Details ENSC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-40	Closed	-$435K	–	1
2021 Q3	$435K	Buy	+40	New	+$782K	100%	1

Other funds holding ENSC

HVCM

HG Vora Capital Management New York $197M AUM 17.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

ECM

Evergreen Capital Management Bellevue, Washington $5.7B AUM 32.06% 1-Year Est. Return

CAM

Cresset Asset Management Chicago, Illinois $27.6B AUM 31.92% 1-Year Est. Return

Founders Fund III Management's ENSC Position: Q4 2021 in Review

Founders Fund III Management sold out of Ensysce Biosciences (ENSC) in Q4 2021, closing a stake of 40 shares — an estimated $435K sold.

Founders Fund III Management first reported a position in ENSC in Q3 2021 and held it in 1 quarter. The position peaked at $435K in Q3 2021. 12 funds tracked by Wall St. Rank hold ENSC as of Q4 2021.

Founders Fund III Management reported no remaining Ensysce Biosciences position as of Q4 2021 after selling out during the quarter.
Founders Fund III Management sold 40 Ensysce Biosciences shares in Q4 2021, an estimated $435K.
Founders Fund III Management first reported a position in Ensysce Biosciences in Q3 2021 and held it in 1 quarter.
Founders Fund III Management's Ensysce Biosciences position peaked at $435K in Q3 2021.
12 funds tracked by Wall St. Rank held Ensysce Biosciences as of Q4 2021.

Based on Founders Fund III Management's 13F filing for Q4 2021.